Fortis loses Supreme Court challenge against forensic audit in Daiichi-Singh brothers case

Fortis Healthcare has suffered a setback after the Supreme Court rejected its challenge against a forensic audit. This legal battle is connected to a long-running dispute with its former owners, the Malvinder and Shivinder Singh brothers. The core issue stems from the sale of Ranbaxy Laboratories to Japanese firm Daiichi Sankyo in 2008. Daiichi had secured a ₹3,500 crore arbitral award against the Singh brothers, alleging they concealed information about quality issues at the company. The forensic audit was ordered to determine if Fortis was liable for these liabilities.

This ruling is significant for investors as it brings the company closer to resolving a major financial overhang. The audit is expected to quantify the potential financial impact on Fortis, which could affect its balance sheet and future profitability. Until the audit results are out, the company remains under a cloud of uncertainty regarding its financial health and ability to service its debt.

Investors should watch for the release of the forensic audit report and the management's commentary on the findings. The outcome will likely dictate the stock's near-term trajectory. Until the company provides clarity on the financial implications, the market may remain cautious, as the resolution of this legacy issue is crucial for restoring investor confidence in the healthcare sector.